In­di­a's Glen­mark Phar­ma­ceu­ti­cals di­vests 75% stake in its API man­u­fac­tur­ing sub­sidiary

Gener­ics pro­duc­er Glen­mark Phar­ma­ceu­ti­cals is di­vest­ing al­most com­plete­ly from its ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API)-man­u­fac­tur­ing sub­sidiary, sell­ing 75% of its shares to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER